Clinical Trials on Hematology in China

Total 1510 results

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Hematologic Malignancy

China
Peking University People's Hospital

Recruiting

ATG Plus Low-dose PT-Cy for GVHD Prevention

Hematologic Malignancy

China
Chinese PLA General Hospital

Completed

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

Solid Tumor | Hematologic Malignancy

China
Sinocelltech Ltd.

Recruiting

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Hematologic Malignancy

China
Peking University People's Hospital

Recruiting

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Hematologic Malignancy | Stem Cell Transplant Complications

China
Children's Cancer Group, China
Shanghai Pudong District Center for Disease Control and Prevention

Recruiting

Vaccination for Children of H&O and Their Parents

Hematologic Malignancy | Solid Tumor, Childhood | Vaccination

China
Westlake Therapeutics

Recruiting

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies (Reboot-101)

Cancer | Solid Tumor | Hematologic Malignancy

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR108 in Hematological Malignancies

Hematologic Malignancy

China
He Huang

Completed

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Hematologic Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Hematologic Malignancy

China
Shanghai Jiao Tong University School of Medicine

Completed

CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

Allogeneic Stem Cell Transplantation | Refractory Hematologic Cancer

China
Sichuan University

Recruiting

Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation

Hematologic Malignancy

China
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Relapsed or Refractory B-cell Hematologic Malignancies

China
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects

Hematologic Malignancy

China
Henan Cancer Hospital
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Hematologic Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Hematological Tumors

China
Beijing Immunochina Medical Science & Technology...

Unknown

Safety and Efficacy Evaluation of IM19 Cells

Hematological Malignancies

China
First Affiliated Hospital of Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University; Sir Run... and other collaborators

Recruiting

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Hematologic Malignancy | Older Patients

China
Peking University People's Hospital
Sanofi

Recruiting

The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation

Hematological Malignancy

China
MEI HENG
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies

B-Cell Lymphoblastic Leukemia/Lymphoma

China
Nanjing University of Traditional Chinese Medicine

Recruiting

Mindfulness-based Virtual Reality Intervention

Hematologic Neoplasms

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Refractory or Recurrent CD30+ Hematologic Malignancies

China
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.
Tongji Hospital

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors

China
Zhejiang University

Not yet recruiting

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

Hematological Malignancies

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
Wei Zhao
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Hematological Neoplasms

China
Ying Wang

Recruiting

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Hematological Malignancies

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

AML | MDS | Old Age; Debility | Hematologic Cancer

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Advanced Solid Tumors and Hematologic Malignancies

China
RenJi Hospital

Recruiting

Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation

Haematological Malignancy

China
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Chinese PLA General Hospital

Recruiting

Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Peripheral Blood Stem Cell Transplantation

China
Shanxi Bethune Hospital

Recruiting

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

Hematological Malignancy

China
Children's Hospital of Fudan University

Recruiting

Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE)

Solid Tumor | Hematological Malignancies

China
Zhejiang University

Recruiting

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Hematological Malignancy

China
Beckman Coulter, Inc.
The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaborators

Recruiting

Evaluation of ClearLLab LS Screening Panel

Hematologic Diseases | Hematologic Neoplasms | Hematologic Malignancy

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Children's Hospital of Fudan University

Unknown

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

Lymphoma | Leukemia

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sixth Affiliated Hospital...

Unknown

Prospective Screening Programme for Malignant Tumors

Malignant Tumor | Hematologic Tests

China

Clinical Trials on Hematology in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations